ArticleRheumatology (Oxford, England)2021
Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis.
Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 42 citations in OpenAlex.
- Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.Rheumatology (Oxford, England) · 2026Article
- Cardiac involvement in systemic sclerosis: mechanisms, manifestations and management.Rheumatology (Oxford, England) · 2026Review
- Coronary microvascular dysfunction in systemic sclerosis: insights from PET-derived myocardial flow reserve.Rheumatology (Oxford, England) · 2026Article
- Primary myocardial involvement in systemic sclerosis: pathophysiology, clinical manifestations and advances in cardiac imaging.Rheumatology (Oxford, England) · 2026Review
- Molecular imaging of fibroblast activation in systemic sclerosis using [European journal of nuclear medicine and molecular imaging · 2026Article
- First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING-SIR registry.European journal of clinical investigation · 2025Article
- Risk of ischaemic and non-ischaemic heart failure in patients with systemic sclerosis: a population-based study.Rheumatology (Oxford, England) · 2025Article
- Coronary microvascular dysfunction in systemic inflammatory diseases: From pathophysiology and prevalence to diagnosis and management.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Review
- Predictive Value of Classical and Emerging Autoantibodies for Cardiac Dysfunction in Systemic Sclerosis: Systematic Review.Journal of clinical medicine · 2025Review
- Characterization of the Left Ventricular Myocardium in Systemic Sclerosis.Journal of clinical medicine · 2025Article
- Determinants of myocardial fibrosis in patients with immune-mediated inflammatory diseases.Advances in rheumatology (London, England) · 2025Article
- Total Hip Arthroplasty Patients With Systemic Sclerosis Have Worse Medical Outcomes But Clinically Similar Implant Survival Independent of Immunomodulatory Therapy.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Article
- Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort.Journal of the American Heart Association · 2025Article
- Quantification of coronary artery calcification in systemic sclerosis using visual ordinal and deep learning scoring: Association with systemic sclerosis clinical features.Seminars in arthritis and rheumatism · 2025Article
- Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications.Current cardiology reports · 2025Review
- Emerging Imaging Techniques for Atherosclerosis in Systemic Immune-Mediated Inflammatory Conditions.Arteriosclerosis, thrombosis, and vascular biology · 2025Review
- Aberrant lipid profiles and lymphocyte counts in systemic sclerosis population, reassessing predictive value for concurrent cardiovascular diseases.Frontiers in immunology · 2025Article
- CAD at the Intersection of Cardiology and Rheumatology: Focus on Cardiovascular Imaging.Methodist DeBakey cardiovascular journal · 2025Review
- Heart involvement in patients with systemic sclerosis-what have we learned about it in the last 5 years.Rheumatology international · 2024Review
- Progression, Management, and Outcome of Aortic Valve Stenosis in Systemic Sclerosis: A Case Series.Journal of cardiovascular development and disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivesSSc primary heart involvement (SSc-pHI) is a significant cause of mortality. We aimed to characterize and identify predictors of subclinical SSc-pHI using cardiovascular MRI.
methodsA total of 83 SSc patients with no history of cardiovascular disease or pulmonary arterial hypertension and 44 healthy controls (HCs) underwent 3 Tesla contrast-enhanced cardiovascular MRI, including T1 mapping and quantitative stress perfusion. High-sensitivity troponin I and N-terminal pro-brain natriuretic peptide were also measured.
resultsCardiovascular MRI revealed a lower myocardial perfusion reserve in the SSc patients compared with HCs {median (interquartile range (IQR)] 1.9 (1.6-2.4) vs 3 (2-3.6), P < 0.001}. Late gadolinium enhancement, indicating focal fibrosis, was observed in 17/83 patients but in none of the HCs, with significantly higher extracellular volume (ECV), suggestive of diffuse fibrosis, in SSc vs HC [mean (s.d.) 31 (4) vs 25 (2), P < 0.001]. Presence of late gadolinium enhancement and higher ECV was associated with skin score [odds ratio (OR) = 1.115, P = 0.048; R2 = 0.353, P = 0.004], and ECV and myocardial perfusion reserve was associated with the presence of digital ulcers at multivariate analysis (R2 = 0.353, P < 0.001; R2 = 0.238, P = 0.011). High-sensitivity troponin I was significantly higher in patients with late gadolinium enhancement, and N-terminal pro-brain natriuretic peptide was associated with ECV (P < 0.05).
conclusionSubclinical SSc-pHI is characterized by myocardial microvasculopathy, diffuse and focal myocardial fibrosis but preserved myocardial contractile function. This subclinical phenotype of SSc-pHI was associated with high-sensitivity troponin I, N-terminal pro-brain natriuretic peptide, SSc disease severity and complicated peripheral vasculopathy. These data provide information regarding the underlying pathophysiological processes and provide a basis for identifying individuals at risk of SSc-pHI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.